Cowen & Co. Maintains Their Buy Rating on Stemline Therapeutics Inc (STML)

By Jason Carr

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STMLResearch Report). The company’s shares closed last Monday at $10.52.

According to, Peaker is a 1-star analyst with an average return of -0.8% and a 39.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Mersana Therapeutics Inc, and Molecular Templates Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stemline Therapeutics Inc with a $27.25 average price target.

See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.84 million. In comparison, last year the company had a GAAP net loss of $18.93 million.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STML in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.